Stem Cell Forum Schedule & Speaker Lineup Announced at BIOCHINA2026

2025 marks a milestone year for stem cell therapies in China. The first domestic stem cell drug, Aimmatoce Injection, achieved regulatory approval in just 18 months. Priced at ¥19,800 per treatment and covered by Beijing’s universal health insurance (up to 65% reimbursement), this breakthrough signals a shift from exclusive, high-cost therapies to broader, accessible care for patients.

🌍 Global and Domestic Landscape

Currently, 16 mesenchymal stem cell (MSC) therapies are available worldwide. In China, MSCs account for 73.6% of approved INDs, making them the primary focus of R&D efforts. Multiple therapies targeting osteoarthritis, liver failure, and refractory anal fistula are entering Phase III trials, with approvals expected by 2026.

⚙️ Technological & Industry Progress

Advances such as fully automated 3D culture technologies and efficient utilization of umbilical cord materials have significantly reduced production costs. Meanwhile, -80°C cold chain logistics allow delivery of cells to most hospitals nationwide within 12 hours, enhancing clinical accessibility.

Despite progress, challenges remain, including inconsistent quality standards, lack of gold-standard functional assays, and difficulties ensuring batch-to-batch process consistency.

📅 BIOCHINA2026 Stem Cell Innovation Forum

Against this backdrop, the Stem Cell Innovation Forum at BIOCHINA2026 offers a premier platform for networking, knowledge exchange, and industry collaboration. Participants will gain insights into the latest clinical advancements, regulatory trends, and technological innovations shaping the future of stem cell therapies.

BIOCHINA2026 Stem Cell Therapeutics Innovation Forum

March 13th

Stem Cell Industry Policies and Translational Practice

15:00–15:20 Presentation: Regulatory Policies

15:20–15:40 Presentation: Lecheng Pilot Program

15:40–16:00 Presentation: Industrialization

16:00–16:20 Presentation: Drug Development for Autoimmune Diseases

16:20–16:40 Presentation: Drug Development for Nervous System Diseases

16:40–17:00 Presentation: Drug Development for Respiratory System Diseases

17:00–18:00 Panel Discussion: Bridging Technology, Clinical Practice, and Regulation – Pathways to Commercialization of Innovative Stem Cell Drugs

March 14th

iPSC Early Research Track

09:00–09:20 Presentation: Clinical Progress of iPSC Therapy for Heart Failure

09:20–09:40 Presentation: Cell Therapy for Parkinson's Disease – Clinical Validation of Next-Generation Therapies and Global Progress

09:40–10:00 Presentation: TBC

10:00–10:20 Presentation: Latest Clinical Progress of Fibroblast Therapy for DDD

iPSC Process Challenges & Quality Control Track

11:20–11:40 Presentation: TBC

11:40–12:00 Presentation: TBC

Lunch & Networking

MSC Development Track

12:00–12:20 Presentation: Phase III Clinical Trial Design of MSC for Knee Osteoarthritis

12:20–13:00 Panel Discussion: Clinical Design Considerations and Regulatory Standards for Knee Osteoarthritis

13:00–13:20 Presentation: Latest Progress and Quality Control of iMSC for Anti-Inflammation and Repair

13:20–13:40 Presentation: Gene-Modified MSC Therapy for Type 2 Diabetes – Latest Progress

13:40–14:00 Presentation: Clinical Progress and International Development Pathways of MSC Therapy for Acute Ischemic Stroke

14:00–14:20 Presentation: Latest Clinical Progress of MSC Therapy for Liver Cirrhosis

14:20–14:40 Presentation: Clinical Exploration of MSC Therapy for Liver Failure

14:40–15:00 Presentation: MSC Quality Control Strategies and Analytical Methods

15:00–16:00 Panel Discussion: Opportunities and Challenges for Stem Cell Drug Development under Regulation 818

Participants & Speakers

• LianJun Shen, GRACELL, SVP
• Xiaowen He, Origincell Therapeutics, CSO
• Xueliang Yu, Starna Therapeutics, Vice President
• Bo Pei, Invivia Biotech, VP
• Fengtao You, PersonGen BioTherapeutics(Suzhou) Co.,Ltd., Director Innovative drug research Institute
• Feifei Qi, Imunopharm Technology Co., Ltd., Co-Founder & CTO
• Shi Zhong, XLifeSc, CSO
• Min Wang, PersonGen, VP
• Eric Xu, TCRCure, VP of MFG
• Yongsheng XU, HELP Therapeutics, Co-Founder & CTO
• Fangfang Zhu, HemaCell Biotechnology Inc., CEO
• Liang Xu, ElpasBio Holdings, VP & CMO & CSO
• Chengyou Dong, Nuwacell Biotech Co., Ltd. (Guangzhou, China), GM Assistant
• Yi Tan, Qilu Cell Therapy, VP and R&D Director
• Zhihui Bai, Shanghai East Hospital, Deputy Director, GMP Laboratory & Director, Quality Control Department

🔗 Register now: https://u.morebio.cn/muyuqmLG